Metformin in PCOS needs further consideration by other investigators. Conflict of interest: None declared. References 1 2 3 4 5 6 7 8 Azziz R. Controversy in clinical en- docrinology: diagnosis of polycystic ovary syndrome: the Rotterdam cri- teria are premature. J Clin Endo- crinol Metab 2006;91:781-5. [1641821] [doi:10.1210/jc.2005- 2153] Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006-11. [10566641] [doi: 10.1210/jc.84.11.4006] Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar- Morreale HF. A prospective study of the prevalence of the polycystic ova- ry syndrome in unselected Cauca- sian women from Spain. J Clin En- docrinol Metab 2000;85:2434-8. [10902790] [doi:10.1210/jc.85.7.2434] Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an un- selected population. J Clin Endo- crinol Metab 2004;89:2745-9. [15181 052] [doi:10.1210/jc.2003- 032046] Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar- Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF; Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syn- drome as a predominantly hyper- androgenic syndrome: an Androgen Excess Society guideline. J Clin En- docrinol Metab 2006;91:4237-45. [16940456] [doi:10.1210/jc.2006- 0178] Dunaif A. Insulin resistance and the polycystic ovary syndrome: mecha- nism and implications for pathogene- sis. Endocr Rev 1997;18:774-800. [9408743] Barber TM, McCarthy MI, Wass JA, Franks S. Obesity and polycystic ova- ry syndrome. Clin Endocrinol (Oxf) 2006;65:137-45. [16886951] [doi: 10.1111/j.1365-2265.2006.02587.x] Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syn- drome at long-term follow-up: a ret- rospective cohort study. Clin Endo- crinol (Oxf) 2000;52:595-600. [10 792339] [doi:10.1046/j.1365-2265. 2000.01000.x] 9 Mehrabian F, Khani B, Kelishadi R, Kermani N. The prevalence of met- abolic syndrome and insulin re- sistance according to the phenotypic subgroups of polycystic ovary syn- drome in a representative sample of Iranian females. J Res Med Sci 2011;16:1-7. 10 Festa A, D'Agostino R Jr., Tracy RP, Haffner SM; Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance ath- erosclerosis study. Diabetes 2002;51:1131-7. [11916936] [doi:10. 2337/diabetes.51.4.1131] 11 Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001;86: 2453-5. [11397838] [doi:10.1210/jc. 86.6.2453] 12 Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen JS. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syn- drome. J Clin Endocrinol Metab 2003;88:4649-54. [14557435] [doi: 10.1210/jc.2002-021688] 13 Bozzini C, Girelli D, Olivieri O, Martinelli N, Bassi A, De Matteis G, Tenuti I, Lotto V, Friso S, Pizzolo F, Corrocher R. Prevalence of body iron excess in the metabolic syn- drome. Diabetes Care 2005;28: 2061-3. [16043762] [doi:10.2337/ diacare.28.8.2061] 14 Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 2004;291:711-7. [14871914] [doi:10. 1001/jama.291.6.711] 15 Escobar-Morreale HF, Luque- Ramírez M, Alvarez-Blasco F, Botel- la-Carretero JI, Sancho J, San Mil- lán JL. Body iron stores are in- creased in overweight and obese women with polycystic ovary syn- drome. Diabetes Care 2005;28:20 42-4. [16043756] [doi:10.2337/diacare.28.8.2042] 16 Botella-Carretero JI, Luque-Ramírez M, Alvarez-Blasco F, San Millán JL, Escobar-Morreale HF. Mutations in the hereditary hemochromatosis gene are not associated with the in- creased body iron stores observed in overweight and obese women with polycystic ovary syndrome. Di- abetes Care 2006;29:2556. [170 65702] [doi:10.2337/dc06-1655] 17 McCarty MF. Hyperinsulinemia may boost both hematocrit and iron ab- sorption by up-regulating activity of hypoxia-inducible factor-1alpha. Med Hypotheses 2003;61:567-73. [14592787] 18 Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI, Sanchón R, San Millán JL, Escobar-Morreale HF. Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of in- sulin resistance and hyperinsulinism and are not a result of reduced menstrual losses. Diabetes Care 2007;30:2309-13. [17536071] [doi: 10.1016/S0306-9877(03)00231-7] 19 Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syn- drome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab 1997; 82:4075-9. [9398716] [doi:10.1210/ jc.82.12.4075] 20 Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syn- drome reduces hyperinsulinemia, insulin resistance, hyperandro- genemia, and systolic blood pres- sure, while facilitating normal men- ses and pregnancy. Metabolism 1994;43:647-54. [8177055] [doi:10. 1016/0026-0495(94)90209-7] 21 Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-43. [10733371] [doi:10.10 56/NEJM200003233421202] 22 Homburg R. Polycystic ovary syn- drome-from gynaecological curiosity to multisystem endocrinopathy. Hum Reprod 1996;11:29-39. [8671153] 23 Bues JB,Polonsky KS and Burant CF. Type 2 diabetes mellitus. In: Larsen, Kronenberg, Melmed, Polonsky (editors): Williams Text- book of Endocrinology. Saunders, Philadelphia, 2003; p.1441. 24 Clinical Guidelines on the Identifica- tion, Evaluation, and Treatment of Overweight and Obesity in Adults-- The Evidence Report. National Insti- tutes of Health. Obes Res 1998; 6:51S-209S. [9813653] 25 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner WWW.ircmj.com Vol 13 July 2011 491